Morphine Sulphate Aurum Pharmaceuticals (Morphine Sulfate)

Morphine Sulfate works by binding as a full agonist to mu‑opioid receptors in the brain and spinal cord. This activation inhibits neuronal firing, reduces the release of excitatory neurotransmitters, and blocks the transmission of pain signals, resulting in analgesia and sedation.

The dose of Morphine Sulfate is individualized by the prescribing clinician based on the severity of pain, the patient’s age, weight, organ function, prior opioid exposure, and response to therapy. No fixed regimen is provided; dosing is adjusted to achieve adequate pain control while minimizing adverse effects.

Safety data for Morphine Sulfate in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or used only when the benefit outweighs the risk. It can cross the placenta and be excreted in breast milk, potentially causing respiratory depression in the newborn; therefore, it should be avoided unless absolutely necessary.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Morphine Sulfate is considered a benchmark opioid with well‑characterised potency and pharmacokinetics. Compared with weaker opioids such as codeine, it provides stronger analgesia at lower milligram doses, but it also carries a higher risk of respiratory depression and dependence. Relative to newer synthetic opioids, morphine has a longer history of clinical use and a well‑understood safety profile.

Morphine Sulfate injectable should be stored at ambient temperature, below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly sealed to maintain sterility.

Morphine Sulfate is supplied as a sterile injectable solution and may be given by intramuscular, intravenous, or subcutaneous injection. The route and rate of administration are determined by the prescriber, based on the clinical situation and required speed of analgesia.

The most serious risks include respiratory depression, severe hypotension, profound sedation, development of physical dependence or addiction, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be closely monitored for signs of respiratory compromise, especially during dose titration or when combined with other depressant agents.

Morphine Sulfate is contraindicated in individuals with known hypersensitivity to morphine or any excipients, in patients with severe respiratory insufficiency, acute or severe asthma, and in those who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for patients with uncontrolled hypertension, head injury, or increased intracranial pressure.